Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aron Goldhirsch

Showing results (1-10 of 283) with videos related to

Pageof 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 29, 2002
An interview with Dr. Aron GoldhirschAron Goldhirsch
Breast (Edinburgh, Scotland)|October 1, 2013
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipientAron Goldhirsch
Nature Reviews. Clinical Oncology|July 9, 2014
Breast cancer: why do women opt for contralateral prophylactic mastectomy?Aron Goldhirsch, Shari Gelber
Current Problems in Cancer|February 6, 2003
Adjuvant systemic therapies for patients with breast cancer: endocrine responsiveness and effects of chemotherapyMarco Colleoni, Aron Goldhirsch
Onkologie|May 29, 2003
Adjuvant chemotherapy in breast cancer: back to the futureMarco Colleoni, Aron Goldhirsch
The Lancet. Oncology|December 24, 2013
Neoadjuvant chemotherapy for breast cancer: any progress?Marco Colleoni, Aron Goldhirsch
Women'S Health (London, England)|October 7, 2009
Breast cancer in young women: climbing for progress in care and knowledgeOlivia Pagani, Aron Goldhirsch
Journal of the National Cancer Institute. Monographs|November 2, 2011
The triple-negative subtype: new ideas for the poorest prognosis breast cancerGiuseppe Curigliano, Aron Goldhirsch
Nature Clinical Practice. Oncology|July 12, 2007
To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancerGiuseppe Curigliano, Aron Goldhirsch
Journal of Surgical Oncology|December 29, 2006
Comparing aromatase inhibitors in the absence of clinical trial results can be misleadingAron Goldhirsch, Karen N Price
Pageof 29

Showing results (1-10 of 283) with videos related to

Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|October 29, 2002
An interview with Dr. Aron GoldhirschAron Goldhirsch
Breast (Edinburgh, Scotland)|October 1, 2013
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipientAron Goldhirsch
Nature Reviews. Clinical Oncology|July 9, 2014
Breast cancer: why do women opt for contralateral prophylactic mastectomy?Aron Goldhirsch, Shari Gelber
Current Problems in Cancer|February 6, 2003
Adjuvant systemic therapies for patients with breast cancer: endocrine responsiveness and effects of chemotherapyMarco Colleoni, Aron Goldhirsch
Onkologie|May 29, 2003
Adjuvant chemotherapy in breast cancer: back to the futureMarco Colleoni, Aron Goldhirsch
The Lancet. Oncology|December 24, 2013
Neoadjuvant chemotherapy for breast cancer: any progress?Marco Colleoni, Aron Goldhirsch
Women'S Health (London, England)|October 7, 2009
Breast cancer in young women: climbing for progress in care and knowledgeOlivia Pagani, Aron Goldhirsch
Journal of the National Cancer Institute. Monographs|November 2, 2011
The triple-negative subtype: new ideas for the poorest prognosis breast cancerGiuseppe Curigliano, Aron Goldhirsch
Nature Clinical Practice. Oncology|July 12, 2007
To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancerGiuseppe Curigliano, Aron Goldhirsch
Journal of Surgical Oncology|December 29, 2006
Comparing aromatase inhibitors in the absence of clinical trial results can be misleadingAron Goldhirsch, Karen N Price
Pageof 29